Inflammation, oxidative stress and wound healing after ablation of atrial fibrillation

Submission date	Recruitment status No longer recruiting	Prospectively registered		
27/11/2007		☐ Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
11/12/2007		[X] Results		
Last Edited	Condition category	Individual participant data		
31/05/2019	Circulatory System			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Bernhard Richter

Contact details

Waehringer Guertel 18-20 Vienna Austria 1090 +43 (0)1 40400 4614 bernhard.richter@meduniwien.ac.at

Additional identifiers

Protocol serial number

07098 (ref. no. of The Medical-Scientific Fund of the Mayor of Vienna)

Study information

Scientific Title

Time course of biochemical markers of inflammation, oxidative stress and wound healing after ablation of atrial fibrillation

Study objectives

- 1. Radiofrequency ablation of Atrial Fibrillation (AF) affects biochemical markers of inflammation, oxidative stress and wound healing
- 2. The ablation-induced changes of the assessed biochemical markers correlate with the ablation-induced structural changes, with the amount of energy applied during ablation and with the AF recurrence rate after ablation

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Ethics Committee of the Medical University of Vienna on the 13th February 2007 (ref: 028/2007) - www.meduniwien.ac.at/ethik.

Study design

Observational, prospective, single centre, longitudinal study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Atrial fibrillation

Interventions

Observational trial:

The included patients will undergo a radiofrequency ablation procedure comprising:

- 1. A CARTO-guided left atrial circumferential ablation
- 2. A Lasso-guided segmental pulmonary vein isolation, and
- 3. Ablation of complex fractionated potentials

Venous blood sampling will be performed before and 6 hours, 24 hours, 48 hours, 7, 28, 90 and 180 days after ablation in order to determine biochemical markers of inflammation, wound healing and oxidative stress. Transthoracal echocardiography and cardiac MRI will be conducted before and 6 months after ablation in order to assess ablation-induced structural changes. Successful ablation will be defined as no recurrence of atrial fibrillation persisting or developing beyond a period of 3 months after ablation.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

- 1. Biochemical markers of inflammation, oxidative stress and wound healing at the above specified timepoints
- 2. Ablation-induced structural atrial changes evaluated by MRI and echocardiography at the above specified timepoints

Key secondary outcome(s))

- 1. Correlation of the assessed biochemical markers with ablation-induced structural changes, energy application data and AF recurrence rate after ablation
- 2. Complications

Completion date

01/08/2008

Eligibility

Key inclusion criteria

- 1. Genders eligible for study: both
- 2. Age older than 18 years
- 3. Symptomatic, drug-resistant paroxysmal atrial fibrillation (self-terminating episodes lasting less than 7 days)
- 4. Patients referred to our department for catheter ablation of atrial fibrillation
- 5. Adequate anticoagulation for at least 1 month prior to admission (oral anticoagulation (target International Normalised Ratio [INR] 2 to 3) or treatment with weight-adjusted low-molecular-weight heparin

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

30

Key exclusion criteria

- 1. Pregnancy
- 2. Ongoing infections
- 3. Intracardiac thrombosis detected by trans-oesophageal echocardiography
- 4. Contraindications to anticoagulation
- 5. History of myocardial infarction or cardiac surgery within the last 3 months prior to admission
- 6. Pacemaker or other contraindications to Magnetic Resonance Imaging (MRI)
- 7. Denial or withdrawal of informed consent
- 8. Life expectancy less than 1 year

Date of first enrolment

30/11/2007

Date of final enrolment

01/08/2008

Locations

Countries of recruitment

Austria

Study participating centre Waehringer Guertel 18-20 Vienna Austria 1090

Sponsor information

Organisation

Medical University of Vienna (Austria)

ROR

https://ror.org/05n3x4p02

Funder(s)

Funder type

Government

Funder Name

The Medical-Scientific Fund of the Mayor of Vienna (Medizinisch-Wissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt Wien) (Austria) (ref: 07098) - http://www.wien.gv.at/fonds/gesundheit/index.htm

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/10/2011	31/05/2019	Yes	No
Results article	results	01/03/2012	31/05/2019	Yes	No